ReviewNature reviews. Microbiology2007
Pathogenic epitopes, heterologous immunity and vaccine design.
Review in Nature reviews. Microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Non-specific immunological effects of selected routine childhood immunisations: systematic review.BMJ (Clinical research ed.) · 2016Pooled it
- Pathogenesis of influenza and SARS-CoV-2 co-infection at the extremes of age: decipher the ominous tales of immune vulnerability.Advanced biotechnology · 2025Review
- Deep learning enhances the prediction of HLA class I-presented CD8Nature machine intelligence · 2025Article
- Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120.Frontiers in immunology · 2025Article
- Computational design and evaluation of a polyvalent vaccine for viral nervous necrosis (VNN) in fish to combat Betanodavirus infection.Scientific reports · 2024Article
- Article
- Developing a universal multi-epitope protein vaccine candidate for enhanced borna virus pandemic preparedness.Frontiers in immunology · 2024Article
- Article
- Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens.Vaccines · 2023Review
- Article
- Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis?Sudanese journal of paediatrics · 2022Review
- Molecular Mimicry of SARS-CoV-2 Spike Protein in the Nervous System: A Bioinformatics Approach.Computational and structural biotechnology journal · 2022Article
- Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens.Frontiers in immunology · 2022Article
- Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19.Frontiers in immunology · 2022Article
- RETRACTED: Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds.Pathogens (Basel, Switzerland) · 2021Article
- Progress towards the development of aExpert review of vaccines · 2021Review
- Strong immunity against COVID-19 in the early two years of age links to frequent immunization of routine vaccines.Science bulletin · 2020Article
- Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors.Frontiers in immunology · 2020Review
- Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.Frontiers in immunology · 2020Article
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might therefore be considered pathogenic. We suggest that the specific removal of such pathogenic epitopes from vaccines might increase their prophylactic potential, while minimizing the risk of side-effects from vaccine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.